{"id":61382,"date":"2024-02-28T07:38:17","date_gmt":"2024-02-28T07:38:17","guid":{"rendered":"https:\/\/medsname.com\/zipsydon\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"zipsydon","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/zipsydon\/","title":{"rendered":"Zipsydon"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Zipsydon?<\/h3>\n
\n

Zipsydon<\/strong> bevat ziprasidone<\/strong> from a WHO-GMP certified manufacturer (Sun Pharma) — an atypical antipsychotic<\/strong> distinguished from peers by lower metabolic side-effect burden<\/strong> (less weight gain, less glucose \/ lipid impact than olanzapine, quetiapine, or risperidone) but highest QT prolongation<\/strong> of the atypicals. Crucial dosing rule: must be taken with a ≥ 500-calorie meal — bioavailability doubles with food<\/strong>. Empty-stomach dosing roughly halves drug exposure and is a common cause of treatment failure. Standard adult dose: 40–80 mg twice daily with food<\/strong> (range 40–160 mg\/day). Schizophrenia (FDA-approved for adults), bipolar mania. Pre-existing QT prolongation, recent MI, uncompensated heart failure, and concurrent QT-prolonging drugs are absolute contraindications<\/strong>. Baseline ECG and electrolyte check before starting.<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> Zipsydon is a atypical antipsychotic<\/strong>, prescribed and titrated over weeks for schizophrenia and acute bipolar mania<\/strong>. It is niet<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — elderly dementia mortality.<\/strong> All antipsychotics (atypical and conventional) carry an FDA black-box warning for increased mortality when used to treat dementia-related psychosis or behavioural disturbance in elderly patients. This medication is not approved<\/strong> for dementia-related symptoms.<\/div>\n

What Is Zipsydon?<\/h2>\n

Zipsydon is an oral capsule of ziprasidone hydrochloride<\/strong> manufactured by Sun Pharma. Ziprasidone (US brand Geodon<\/strong>) was launched by Pfizer in 2001 as an atypical antipsychotic with a distinctive favourable metabolic profile. It is a D2<\/sub> and 5-HT2A<\/sub> antagonist with potent 5-HT1A<\/sub> partial agonist activity<\/strong>, plus serotonin \/ norepinephrine reuptake inhibition (the SNRI-like component). The favourable metabolic profile is the main advantage; the QT prolongation and food-dependent absorption are the main limitations.<\/p>\n

Goedgekeurde indicaties<\/h2>\n